Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
for EPP
15 locations incl. Huntington Beach
Sponsor: Tanabe Pharma America, Inc.
Sex: All·Age: 12 - 75
Code: NCT05005975·Phase 3·Recruiting